WallStreetZenWallStreetZen

NASDAQ: PCSA
Processa Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PCSA stock forecasts and price targets.

Forecast return on equity

Is PCSA forecast to generate an efficient return?

Forecast return on assets

Is PCSA forecast to generate an efficient return on assets?

Company
N/A
Industry
23.04%

PCSA earnings per share forecast

What is PCSA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$3.83
Avg 2 year Forecast
-$5.36

PCSA revenue forecast

What is PCSA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

PCSA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PCSA$2.15N/AN/A
DRMA$1.47N/AN/A
CDIO$1.99N/AN/A
ENVB$1.31N/AN/A
CVKD$1.64$13.00+692.68%Buy
View Top Biotech Stocks

Processa Pharmaceuticals Stock Forecast FAQ

What is PCSA's earnings growth forecast for 2026-2027?

(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.

Processa Pharmaceuticals's earnings in 2026 is -$13,438,184.On average, 3 Wall Street analysts forecast PCSA's earnings for 2026 to be -$10,684,701, with the lowest PCSA earnings forecast at -$10,265,694, and the highest PCSA earnings forecast at -$10,998,957.

In 2027, PCSA is forecast to generate -$14,958,582 in earnings, with the lowest earnings forecast at -$14,371,971 and the highest earnings forecast at -$15,398,540.

If you're new to stock investing, here's how to buy Processa Pharmaceuticals stock.

What is PCSA's revenue growth forecast for 2026-2029?

(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.3%.

Processa Pharmaceuticals's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast PCSA's revenue for 2026 to be $0, with the lowest PCSA revenue forecast at $0, and the highest PCSA revenue forecast at $0. On average, 3 Wall Street analysts forecast PCSA's revenue for 2028 to be $0, with the lowest PCSA revenue forecast at $0, and the highest PCSA revenue forecast at $0.

In 2029, PCSA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PCSA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PCSA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.04%.

What is PCSA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: PCSA) Processa Pharmaceuticals's current Earnings Per Share (EPS) is -$4.39. On average, analysts forecast that PCSA's EPS will be -$3.83 for 2026, with the lowest EPS forecast at -$3.68, and the highest EPS forecast at -$3.94. In 2027, PCSA's EPS is forecast to hit -$5.36 (min: -$5.15, max: -$5.51).

What is PCSA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PCSA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.